316 related articles for article (PubMed ID: 8698856)
1. Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity.
Minotti G; Mancuso C; Frustaci A; Mordente A; Santini SA; Calafiore AM; Liberi G; Gentiloni N
J Clin Invest; 1996 Aug; 98(3):650-61. PubMed ID: 8698856
[TBL] [Abstract][Full Text] [Related]
2. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
3. The influence of doxorubicin and 4'-epi-doxorubicin on lipid peroxidation in mouse heart, lungs and liver. Part II.
Pierściński G; Drzewoski J; Nowak D
Pol J Pharmacol; 1994; 46(1-2):55-9. PubMed ID: 7981772
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines.
Menna P; Salvatorelli E; Giampietro R; Liberi G; Teodori G; Calafiore AM; Minotti G
Chem Res Toxicol; 2002 Sep; 15(9):1179-89. PubMed ID: 12230412
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of Spirulina against doxorubicin-induced cardiotoxicity.
Khan M; Shobha JC; Mohan IK; Naidu MU; Sundaram C; Singh S; Kuppusamy P; Kutala VK
Phytother Res; 2005 Dec; 19(12):1030-7. PubMed ID: 16372368
[TBL] [Abstract][Full Text] [Related]
6. Effect of doxorubicin on lipid peroxide levels in tissues of mice.
Sazuka Y; Yoshikawa K; Tanizawa H; Takino Y
Jpn J Cancer Res; 1987 Nov; 78(11):1281-6. PubMed ID: 3121563
[TBL] [Abstract][Full Text] [Related]
7. Acute exercise protects against doxorubicin cardiotoxicity.
Wonders KY; Hydock DS; Schneider CM; Hayward R
Integr Cancer Ther; 2008 Sep; 7(3):147-54. PubMed ID: 18815146
[TBL] [Abstract][Full Text] [Related]
8. Conjugated dienes in selected organs of mice treated with doxorubicin and 4'-epi-doxorubicin. Part I.
Drzewoski J; Pierściński G; Nowak D
Pol J Pharmacol; 1994; 46(1-2):51-4. PubMed ID: 7981771
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
10. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
Mohamed HE; Asker ME; Ali SI; el-Fattah TM
J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
[TBL] [Abstract][Full Text] [Related]
11. Cytoprotective agents for anthracyclines.
Dorr RT
Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
[TBL] [Abstract][Full Text] [Related]
12. Cytoprotective effect of anthocyanins against doxorubicin-induced toxicity in H9c2 cardiomyocytes in relation to their antioxidant activities.
Choi EH; Chang HJ; Cho JY; Chun HS
Food Chem Toxicol; 2007 Oct; 45(10):1873-81. PubMed ID: 17524543
[TBL] [Abstract][Full Text] [Related]
13. Dietary fish oil does not prevent doxorubicin-induced cardiomyopathy in rats.
Matsui H; Morishima I; Hayashi K; Kamiya H; Saburi Y; Okumura K
Can J Cardiol; 2002 Mar; 18(3):279-86. PubMed ID: 11907617
[TBL] [Abstract][Full Text] [Related]
14. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity.
El-Demerdash E; Ali AA; Sayed-Ahmed MM; Osman AM
Cancer Chemother Pharmacol; 2003 Nov; 52(5):411-6. PubMed ID: 12879278
[TBL] [Abstract][Full Text] [Related]
15. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of Terminalia arjuna against Doxorubicin-induced cardiotoxicity.
Singh G; Singh AT; Abraham A; Bhat B; Mukherjee A; Verma R; Agarwal SK; Jha S; Mukherjee R; Burman AC
J Ethnopharmacol; 2008 Apr; 117(1):123-9. PubMed ID: 18346858
[TBL] [Abstract][Full Text] [Related]
17. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: role of aminoguanidine.
Abd El-Gawad HM; El-Sawalhi MM
J Biochem Mol Toxicol; 2004; 18(2):69-77. PubMed ID: 15122648
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of buthionine sulfoximine-enhanced doxorubicin toxicity in metallothionein overexpressing transgenic mouse heart.
Wu HY; Kang YJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):515-20. PubMed ID: 9808675
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G
Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]